Tadalafil 5 mg Daily Treatment for Type 1 Diabetic Premenopausal Women Affected by Sexual Genital Arousal Disorder

• Published in: Journal of sexual medicine 2012-08, Vol.9 (8), p.2057-2065
• Main Authors: Caruso, Salvatore, Cicero, Carla, Romano, Mattea, Lo Presti, Lucia, Ventura, Betty, Malandrino, Chiara
• Format: Article
• Language: English
• Subjects: Adult; Arousal - drug effects; Carbolines - administration & dosage; Clitoral Color Doppler; Clitoris - blood supply; Diabetes Mellitus, Type 1 - physiopathology; Diabetic Angiopathies - drug therapy; Diabetic Angiopathies - physiopathology; Drug Administration Schedule; Female; Female Sexual Dysfunction; Humans; Orgasm - drug effects; Premenopause - physiology; Prospective Studies; Quality of Life; Sexual Behavior - drug effects; Sexual Dysfunctions, Psychological - drug therapy; Sexual Dysfunctions, Psychological - etiology; Sexual Genital Arousal Dysfunction; Surveys and Questionnaires; Tadalafil; Type 1 Diabetes; Vasodilator Agents - administration & dosage; Young Adult
• ISSN: 1743-6095; 1743-6109
• DOI: 10.1111/j.1743-6109.2012.02777.x

Type 1 diabetic women may be affected by sexual dysfunction, mainly due to peripheral vascular disease. To determine whether daily tadalafil 5 mg is effective in type 1 premenopausal women affected by sexual genital arousal disorder. Thirty‐three volunteers were enrolled in a 12‐week daily tadalafil 5 mg prospective study. The efficacy of daily tadalafil 5 mg on sexual genital arousal (primary end point), and desire, orgasm, enjoyment and frequency of sexual activity, and genital pain (secondary end points) were assessed (i) subjectively by the Short Personal Experiences Questionnaire; and (ii) objectively by translabial color Doppler sonography of clitoral blood flow. Moreover, the Short Form‐36 questionnaire was used to assess Quality of Life (QoL). Thirty‐two women completed the study. Women reported a QoL improvement at the 12th week follow‐up (P